Impaired Fas response and autoimmunity in Pten(+/-) mice

Science

Volumn 285, Issue 5436, 1999, Pages 2122-2125

  Di Cristofano, Antonio ^a   Kotsi, Paraskevi ^a   Peng, Yu Feng ^b   Cordon Cardo, Carlos ^a   Elkon, Keith B ^b   Pandolfi, Pier Paolo ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; HISTOPATHOLOGY; IMMUNE COMPLEX DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR SUPPRESSOR GENE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIGENS, CD95; APOPTOSIS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; FEMALE; HETEROZYGOTE; IMMUNOGLOBULIN G; KIDNEY DISEASES; KIDNEY GLOMERULUS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; T-LYMPHOCYTES; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA;

EID: 0032843540     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.285.5436.2122     Document Type: Article

References (39)

1. J. Li et al., Science 275, 1943 (1997); P A. Steck et al., Nature Genet. 15, 356 (1997).
2. J. Li et al., Science 275, 1943 (1997); P A. Steck et al., Nature Genet. 15, 356 (1997).
3. B. K. Rasheed et al., Cancer Res. 57, 4187 (1997); H. Tashiro et al., ibid., p. 3935; P. Cairns et al., ibid., p. 4997; E. Rhei et al., ibid., p. 3657.
4. B. K. Rasheed et al., Cancer Res. 57, 4187 (1997); H. Tashiro et al., ibid., p. 3935; P. Cairns et al., ibid., p. 4997; E. Rhei et al., ibid., p. 3657.
5. B. K. Rasheed et al., Cancer Res. 57, 4187 (1997); H. Tashiro et al., ibid., p. 3935; P. Cairns et al., ibid., p. 4997; E. Rhei et al., ibid., p. 3657.
6. B. K. Rasheed et al., Cancer Res. 57, 4187 (1997); H. Tashiro et al., ibid., p. 3935; P. Cairns et al., ibid., p. 4997; E. Rhei et al., ibid., p. 3657.
7. D. Liaw et al., Nature Genet. 16, 64 (1997); D. J. Marsh et al., J. Med. Genet. 35, 881 (1998); D. J. Marsh et al., Hum. Mol. Genet. 7, 507 (1998).
8. D. Liaw et al., Nature Genet. 16, 64 (1997); D. J. Marsh et al., J. Med. Genet. 35, 881 (1998); D. J. Marsh et al., Hum. Mol. Genet. 7, 507 (1998).
9. D. Liaw et al., Nature Genet. 16, 64 (1997); D. J. Marsh et al., J. Med. Genet. 35, 881 (1998); D. J. Marsh et al., Hum. Mol. Genet. 7, 507 (1998).
10. A. Di Cristofano, B. Pesce, C. Cordon-Cardo, P. P. Pandolfi, Nature Genet. 19, 348 (1998); A. Suzuki et al., Curr. Biol. 8, 1169 (1998); K. Podsypanina et al., Proc. Natl. Acad. Sci. U.S.A. 96, 1563 (1999).
11. A. Di Cristofano, B. Pesce, C. Cordon-Cardo, P. P. Pandolfi, Nature Genet. 19, 348 (1998); A. Suzuki et al., Curr. Biol. 8, 1169 (1998); K. Podsypanina et al., Proc. Natl. Acad. Sci. U.S.A. 96, 1563 (1999).
12. A. Di Cristofano, B. Pesce, C. Cordon-Cardo, P. P. Pandolfi, Nature Genet. 19, 348 (1998); A. Suzuki et al., Curr. Biol. 8, 1169 (1998); K. Podsypanina et al., Proc. Natl. Acad. Sci. U.S.A. 96, 1563 (1999).
13. T. Maehama and J. E. Dixon, J. Biol. Chem. 273, 13375 (1998).
14. M. P. Myers et al., Proc. Natl. Acad. Sci. U.S.A. 95, 13513 (1998); J. Li et al., Cancer Res. 58, 5667 (1998); P. L. Dahia et al., Hum. Mol. Genet. 8, 185 (1999); V. Stambolic et al., Cell 95, 29 (1998).
15. M. P. Myers et al., Proc. Natl. Acad. Sci. U.S.A. 95, 13513 (1998); J. Li et al., Cancer Res. 58, 5667 (1998); P. L. Dahia et al., Hum. Mol. Genet. 8, 185 (1999); V. Stambolic et al., Cell 95, 29 (1998).
16. M. P. Myers et al., Proc. Natl. Acad. Sci. U.S.A. 95, 13513 (1998); J. Li et al., Cancer Res. 58, 5667 (1998); P. L. Dahia et al., Hum. Mol. Genet. 8, 185 (1999); V. Stambolic et al., Cell 95, 29 (1998).
17. M. P. Myers et al., Proc. Natl. Acad. Sci. U.S.A. 95, 13513 (1998); J. Li et al., Cancer Res. 58, 5667 (1998); P. L. Dahia et al., Hum. Mol. Genet. 8, 185 (1999); V. Stambolic et al., Cell 95, 29 (1998).
18. Tissue samples were fixed in 10% buffered formalin. Sections (5 μm) were stained with hematoxylin and eosin (H&E). Immunophenotyping was done with an avidin-biotin immunoperoxidase technique. Anti-CD3 (purified rabbit serum, 1:1000; Dako), and anti-B220 (rat monoclonal, 1:1000; PharMingen) were incubated overnight at 4°C. Samples were later incubated with biotinylated secondary antibodies (Vector Labs) for 30 min (goat antibody to rabbit IgG, 1:100; rabbit antibody to rat IgG, 1:100), and then with avidin-biotin peroxidase (1:25 dilution, Vector Labs) for 30 min. Diaminobenzadine was used as the chromogen and hematoxylin was used as the counterstain.
19. Mice harboring mutations in the Fas (lpr) or Fas ligand (gld) genes develop splenomegaly and lymphoadenopathy due to massive lymphocyte accumulation and autoimmune nephritis in some genetic backgrounds [R. Watanabe-Fukunaga et al., Nature 356, 314 (1992); T. Takahashi et al., Cell 76, 969 (1994)]. Human autoimmune lymphoproliferative disorder is also characterized by mutations in these genes [M. S. Lim et al., Am. J. Pathol. 153, 1541 (1998)]. NZB/W mice, considered a model for human systemic lupus erythematosus, develop lymphoadenopathy and lethal glomerulonephritis with earlier onset in females [L. Morel and E. K. Wakeland, Curr. Opin. Immunol. 10, 718 (1998)]. Mice with a disrupted interleukin-2 (IL-2)/IL-2 receptor system show splenomegaly and lymphoadenopathy, autoantibody production, and impaired Fas-dependent apoptosis [D. M. Willerford et al., Immunity 3, 521 (1995); B. Sadlack et al., Cell 75, 253 (1993)].
20. Mice harboring mutations in the Fas (lpr) or Fas ligand (gld) genes develop splenomegaly and lymphoadenopathy due to massive lymphocyte accumulation and autoimmune nephritis in some genetic backgrounds [R. Watanabe-Fukunaga et al., Nature 356, 314 (1992); T. Takahashi et al., Cell 76, 969 (1994)]. Human autoimmune lymphoproliferative disorder is also characterized by mutations in these genes [M. S. Lim et al., Am. J. Pathol. 153, 1541 (1998)]. NZB/W mice, considered a model for human systemic lupus erythematosus, develop lymphoadenopathy and lethal glomerulonephritis with earlier onset in females [L. Morel and E. K. Wakeland, Curr. Opin. Immunol. 10, 718 (1998)]. Mice with a disrupted interleukin-2 (IL-2)/IL-2 receptor system show splenomegaly and lymphoadenopathy, autoantibody production, and impaired Fas-dependent apoptosis [D. M. Willerford et al., Immunity 3, 521 (1995); B. Sadlack et al., Cell 75, 253 (1993)].
21. Mice harboring mutations in the Fas (lpr) or Fas ligand (gld) genes develop splenomegaly and lymphoadenopathy due to massive lymphocyte accumulation and autoimmune nephritis in some genetic backgrounds [R. Watanabe-Fukunaga et al., Nature 356, 314 (1992); T. Takahashi et al., Cell 76, 969 (1994)]. Human autoimmune lymphoproliferative disorder is also characterized by mutations in these genes [M. S. Lim et al., Am. J. Pathol. 153, 1541 (1998)]. NZB/W mice, considered a model for human systemic lupus erythematosus, develop lymphoadenopathy and lethal glomerulonephritis with earlier onset in females [L. Morel and E. K. Wakeland, Curr. Opin. Immunol. 10, 718 (1998)]. Mice with a disrupted interleukin-2 (IL-2)/IL-2 receptor system show splenomegaly and lymphoadenopathy, autoantibody production, and impaired Fas-dependent apoptosis [D. M. Willerford et al., Immunity 3, 521 (1995); B. Sadlack et al., Cell 75, 253 (1993)].
22. Mice harboring mutations in the Fas (lpr) or Fas ligand (gld) genes develop splenomegaly and lymphoadenopathy due to massive lymphocyte accumulation and autoimmune nephritis in some genetic backgrounds [R. Watanabe-Fukunaga et al., Nature 356, 314 (1992); T. Takahashi et al., Cell 76, 969 (1994)]. Human autoimmune lymphoproliferative disorder is also characterized by mutations in these genes [M. S. Lim et al., Am. J. Pathol. 153, 1541 (1998)]. NZB/W mice, considered a model for human systemic lupus erythematosus, develop lymphoadenopathy and lethal glomerulonephritis with earlier onset in females [L. Morel and E. K. Wakeland, Curr. Opin. Immunol. 10, 718 (1998)]. Mice with a disrupted interleukin-2 (IL-2)/IL-2 receptor system show splenomegaly and lymphoadenopathy, autoantibody production, and impaired Fas-dependent apoptosis [D. M. Willerford et al., Immunity 3, 521 (1995); B. Sadlack et al., Cell 75, 253 (1993)].
23. Mice harboring mutations in the Fas (lpr) or Fas ligand (gld) genes develop splenomegaly and lymphoadenopathy due to massive lymphocyte accumulation and autoimmune nephritis in some genetic backgrounds [R. Watanabe-Fukunaga et al., Nature 356, 314 (1992); T. Takahashi et al., Cell 76, 969 (1994)]. Human autoimmune lymphoproliferative disorder is also characterized by mutations in these genes [M. S. Lim et al., Am. J. Pathol. 153, 1541 (1998)]. NZB/W mice, considered a model for human systemic lupus erythematosus, develop lymphoadenopathy and lethal glomerulonephritis with earlier onset in females [L. Morel and E. K. Wakeland, Curr. Opin. Immunol. 10, 718 (1998)]. Mice with a disrupted interleukin-2 (IL-2)/IL-2 receptor system show splenomegaly and lymphoadenopathy, autoantibody production, and impaired Fas-dependent apoptosis [D. M. Willerford et al., Immunity 3, 521 (1995); B. Sadlack et al., Cell 75, 253 (1993)].
24. Mice harboring mutations in the Fas (lpr) or Fas ligand (gld) genes develop splenomegaly and lymphoadenopathy due to massive lymphocyte accumulation and autoimmune nephritis in some genetic backgrounds [R. Watanabe-Fukunaga et al., Nature 356, 314 (1992); T. Takahashi et al., Cell 76, 969 (1994)]. Human autoimmune lymphoproliferative disorder is also characterized by mutations in these genes [M. S. Lim et al., Am. J. Pathol. 153, 1541 (1998)]. NZB/W mice, considered a model for human systemic lupus erythematosus, develop lymphoadenopathy and lethal glomerulonephritis with earlier onset in females [L. Morel and E. K. Wakeland, Curr. Opin. Immunol. 10, 718 (1998)]. Mice with a disrupted interleukin-2 (IL-2)/IL-2 receptor system show splenomegaly and lymphoadenopathy, autoantibody production, and impaired Fas-dependent apoptosis [D. M. Willerford et al., Immunity 3, 521 (1995); B. Sadlack et al., Cell 75, 253 (1993)].
25. +/- mice were fixed with cold acetone and blocked in phosphate-buffered saline (PBS) with 0.1% Triton X-100 and 10% goat serum at room temperature. The samples were then stained with Texas Red-conjugated goat antibody to mouse IgG (Jackson Immunoresearch) for 1 hour at room temperature. ANAs were detected by indirect immunofluorescence on HEp-2 cells. For these assays, sera were diluted 1:50. Total IgG and anti-ssDNA autoantibodies were quantified by enzyme-linked immunosorbent assay (ELISA) as described [D. Mevorach, J. L. Zhou, X. Song, K. B. Elkon, J. Exp. Med. 188, 387 (1998)], with a 1:100 dilution of the sera. All the data were analyzed by Student's t test Urine samples were spotted on Chemstrip Test Dipstix (Boehringer); values of 2+ or more were considered as positive.
26. L. Reininger et al., J. Exp. Med. 184, 853 (1996).
27. Single-cell suspensions of spleen and lymph nodes were depleted of mature red blood cells by hypotonic lysis and were stained with the following conjugated antibodies: anti-CD3ε, anti-B220, anti-Thyl, anti-CD4, anti-CD8a (lineage markers); anti-CD5, anti-CD95, anti-CD54, anti-CD69, anti-CD44, anti-B7-2 (activation markers). All antibodies were from PharMingen. Flow cytometry was done with a FAC-Scan (Becton Dickinson) and the data were analyzed with CELLQuest software (Becton Dickinson).
28. J. S. Levine and J. S. Koh, Semin. Nephrol. 19, 34 (1999); L. Van Parijs and A. K. Abbas, Curt. Opin. Immunol. 8, 355 (1996); K. B. Elkon and A. Marshak-Rothstein, ibid., p. 852; J. P. Weintraub, R. A. Eisenberg, P. L. Cohen, J. Immunol. 159, 4117 (1997).
29. J. S. Levine and J. S. Koh, Semin. Nephrol. 19, 34 (1999); L. Van Parijs and A. K. Abbas, Curt. Opin. Immunol. 8, 355 (1996); K. B. Elkon and A. Marshak-Rothstein, ibid., p. 852; J. P. Weintraub, R. A. Eisenberg, P. L. Cohen, J. Immunol. 159, 4117 (1997).
30. J. S. Levine and J. S. Koh, Semin. Nephrol. 19, 34 (1999); L. Van Parijs and A. K. Abbas, Curt. Opin. Immunol. 8, 355 (1996); K. B. Elkon and A. Marshak-Rothstein, ibid., p. 852; J. P. Weintraub, R. A. Eisenberg, P. L. Cohen, J. Immunol. 159, 4117 (1997).
31. J. S. Levine and J. S. Koh, Semin. Nephrol. 19, 34 (1999); L. Van Parijs and A. K. Abbas, Curt. Opin. Immunol. 8, 355 (1996); K. B. Elkon and A. Marshak-Rothstein, ibid., p. 852; J. P. Weintraub, R. A. Eisenberg, P. L. Cohen, J. Immunol. 159, 4117 (1997).
32. 3H]thymidine (1 μCi per well, Amersham) was added, and the cells were harvested 16 hours later for analysis. Addition of recombinant mouse IL-2 (1 to 100 U/ml, Boehringer) to the Con A-stimulated cells did not alter the results.
33. + cells were activated as above or in the presence of LPS (100 μg/ml). At day 3 (LPS) or day 4 (CD3), viable cells were purified by Ficoll (Pharmacia) gradient centrifugation and plated on cross-linked anti-CD3ε (10 μg/ml) or anti-CD95 (1 to 10 μg/ml) (Jo2, PharMingen). Apoptosis was determined after 24 or 48 hours by in situ TUNEL In some cases cells were incubated 30 min at 37°C in the presence of 1 μM wortmannin (Sigma) before anti-CD95 treatment. PEFs were derived from 14.5-day-old embryos. Anti-CD95 was added at 100 ng/ml in the presence of actinomycin D (0.25 μg/ml). Cell death was determined 18 hours later by trypan blue exclusion and Annexin V staining (PharMingen).
34. 473) and anti-Akt (New England Biolabs); anti-PARP (PharMingen); and anti-β-actin (Sigma).
35. C. Widmann, S. Gibson, G. L. Johnson, J. Biol. Chem. 273, 7141 (1998); Y. A. Lazebnik et al. Nature 371, 346 (1994).
36. C. Widmann, S. Gibson, G. L. Johnson, J. Biol. Chem. 273, 7141 (1998); Y. A. Lazebnik et al. Nature 371, 346 (1994).
37. J. M. Penninger and G. Kroemer, Adv. Immunol. 68, 51 (1998); M. J. Lenardo, Semin. Immunol. 9, 1 (1997).
38. J. M. Penninger and G. Kroemer, Adv. Immunol. 68, 51 (1998); M. J. Lenardo, Semin. Immunol. 9, 1 (1997).
39. We thank J. L. Zhou for help with the ELISA, M. Jiao for preparation of pathological samples, and M. De Acetis for help with protein immunoblots and mice. P.P.P. is a Scholar of the Leukemia Society of America. Supported by National Cancer Institute grants CA-08748 and CA-82328 and the I. T. Hirschl/M. Weill-Caulier Foundation (P.P.P.), and by NIH grant AR45482 and the Systemic Lupus Ezythemetosus Foundation, New York (K.B.E.).